Journal
THROMBOSIS AND HAEMOSTASIS
Volume 103, Issue 1, Pages 224-233Publisher
GEORG THIEME VERLAG KG
DOI: 10.1160/TH09-06-0400
Keywords
Tissue factor / factor VII; animal models; arterial thrombosis; coagulation inhibitors
Categories
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R44HL082397] Funding Source: NIH RePORTER
- NHLBI NIH HHS [R44 HL082397, R44 HL082397-03] Funding Source: Medline
Ask authors/readers for more resources
Tissue factor (TF) antagonists targeting the factor VII (FVII) binding domain have been shown to interrupt acute vascular thrombus formation without impairing haemostasis in non-human primates. In this study, we evaluate whether a human/mouse chimeric monoclonal antibody (ALT-836, formerly known as Sunol-cH36) blocking the factor X/factor IX (FX/FIX) binding site of tissue factor could achieve similar clinical benefits in an arterial thrombosis model induced by surgical endarterectomy in chimpanzees. In this model, sequential surgical endarterectomies on right and left superficial femoral arteries were performed 30 days apart in five chimpanzees. A bolus (1 mg/kg) of ALT-836 was injected intravenously immediately preceding the restoration of flow in the endarterectomised femoral artery. Pre-surgical labelling of autologous platelets using In-111-Oxine and post-surgical gamma camera imaging of In-111-platelet deposition at endarterectomy sites was performed. The manipulated arterial segments were harvested for patency analysis 30 days following surgery. The results indicate that ALT-836 was highly effective at reducing acute vascular thrombosis, with no significant variations in surgical blood loss and template-bleeding time in the treated group compared to the control animals. These data suggest that ALT-836 is an effective and safe antithrombotic agent in preventing TF-initiated vascular thrombogenesis without compromising haemostasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available